Simplified HIV treatment for people living with HIV
Part of Immune system & allergy, Infections clinical trials.
This trial looks at whether a simpler set of HIV medicines works for people with confirmed HIV-1 infection. It may help by making treatment easier to follow, while monitoring health with regular blood tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed HIV-1 infection
- You agree to take the trial’s simplified HIV medicine plan
- You agree to have a CD4 blood test at least once every 6 months
- You have not taken part in an HIV vaccine trial or taken other drug trials in the last 3 months
- You can attend regular follow-up visits during the study
- You do not have known drug resistance or an allergy to LPV/r or 3TC
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether taking dolutegravir plus lamivudine (a simpler two-drug regimen) can work as well as a standard three-drug HIV regimen for people who have reasons they can’t stay on the usual medicines. You may be offered free treatment if you meet the safety checks and can attend follow-up visits.
This study tests two ways to simplify your HIV and hepatitis B treatment while keeping the viruses controlled. By switching to a simpler combination, the goal is to maintain low viral levels and reduce the number of medicines you take.
This study tests if a two-drug HIV regimen (darunavir/cobicistat plus lamivudine) works as well as a standard three-drug regimen in men whose HIV is already well-controlled. If effective, this could mean taking fewer medications.
This study tests a new combination medicine for people with HIV who have never taken treatment. It aims to see if it is safe and helps reduce the amount of virus in the blood.
This trial tests different ways to manage “virologic failure,” meaning HIV viral load stays high while taking TLD (a common HIV medicine combination). It may help people better control the virus and improve treatment results, especially in parts of sub-Saharan Africa.
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
Hear when a new HIV/AIDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.